Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 38Neoplasm Metastasis 37Multiple Myeloma 29Lymphoma 23Colorectal Neoplasms 18Breast Neoplasms 18Pancreatic Neoplasms 17Prostatic Neoplasms 16Myelodysplastic Syndromes 16Lymphoma, Large B-Cell, Diffuse 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Burkitt Lymphoma 15Triple Negative Breast Neoplasms 13Melanoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Ovarian Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Sarcoma 10Neuroblastoma 9Neoplasms 9Glioma 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, T-Cell 8Leukemia, Biphenotypic, Acute 8Fallopian Tube Neoplasms 8Endometrial Neoplasms 8Myeloproliferative Disorders 7Lymphoma, Non-Hodgkin 7

Interventions

berzosertib 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clinical Stage III Gastric Cancer AJCC v8 × Biopsy × 90 days × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡